← Eichor
Study identifier: NCT07343531 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study Of Moderately Hypo-Fractionated External-beam Radiotherapy With Concurrent Chemotherapy and High Dose Rate Brachytherapy In Cervical Cancer

Condition: Cervical Carcinoma Stage III · Cervical Carcinoma Stage IIB · Cervical Carcinoma Stage II  ·  Sponsor: Ain Shams University

PhaseNA
Planned participants30
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Cancer of the uterine cervix is one of the most common gynecologic cancer diagnosis and cause of death among gynecologic cancers worldwide .The two major histologic types of cervical cancer are squamous cell carcinoma, adenocarcinoma and the preinvasive disease that corresponds with these histologies share many of the same risk factors . Cancer cervix can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment, which can improve survival rates, reduce the risk of treatment failure, reduce costs and patient exposure.

This description comes directly from the study's public registry record.

Talk to the study team

Manar Adel, master degree  ·  +201066760941  ·  manar.adel@med.asu.edu.eg

Always discuss trial participation with your own doctor first.

Locations (1)

Ainshams UniversityCairo, Cairo Governorate, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07343531